ST266 is a first-of-its-kind, multi-targeted, non-cellular platform biologic with the potential to improve patients’ outcomes across a range of challenging diseases and conditions in ophthalmology, neurology, dermatology—and more. Many of these conditions currently have no or limited therapeutic options in part because they are often too complex to be treated with traditional “one-drug, one-target” therapies.
ST266 is produced by collecting the secretome from a novel population of cells generated by a proprietary method of culturing amnion-derived epithelial cells from donated full-term placentas, normally discarded after birth. The cells produce many of the biologic factors found in amniotic fluid that may be responsible for the remarkable healing capabilities and lack of scarring observed following in-utero fetal surgery.
Noveome owns 51 U.S. patents protecting ST266 and the cells and process for producing it, as well as methods of use and many other pending patent applications. In addition, Noveome has over 40 granted patents and several pending applications in major global markets including Europe, Japan, China and Canada.